S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
America's Worst Nightmare: A Major Financial Crisis Looms (Ad)
How major US stock indexes fared Friday 6/9/2023
MarketBeat Week in Review – 6/4 - 6/9
The single greatest medical breakthrough of all time? (Ad)
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
FuelCell Is Back To Realistic Valuation
The single greatest medical breakthrough of all time? (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:ADMS

Adamas Pharmaceuticals (ADMS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$8.22
$8.22
50-Day Range
$7.97
$8.23
52-Week Range
$4.02
$9.15
Volume
N/A
Average Volume
692,487 shs
Market Capitalization
$376.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADMS stock logo

About Adamas Pharmaceuticals (NASDAQ:ADMS) Stock

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Receive ADMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMS Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Adamas One Corp (JEWL)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Why Supernus' Acquisition of Adamas Is a Smart Move
See More Headlines


ADMS Company Calendar

Last Earnings
11/11/2021
Today
6/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADMS
Employees
138
Year Founded
2002

Profitability

Net Income
$-57,400,000.00
Pretax Margin
-71.11%

Debt

Sales & Book Value

Annual Sales
$74.46 million
Book Value
($0.47) per share

Miscellaneous

Free Float
37,133,000
Market Cap
$376.37 million
Optionable
Optionable
Beta
2.82

Social Links


Key Executives

  • Neil F. McFarlane
    Chief Executive Officer & Director
  • Christopher B. PrentissChristopher B. Prentiss
    Chief Financial Officer
  • Adrian Quartel
    Chief Medical Officer
  • Vijay ShreedharVijay Shreedhar
    Chief Commercial Officer
  • Jill M. Jene
    Head-Corporate Development & Strategy













ADMS Stock - Frequently Asked Questions

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) posted its quarterly earnings data on Thursday, November, 11th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.21. The specialty pharmaceutical company earned $25.90 million during the quarter, compared to the consensus estimate of $25.07 million.

What is Neil McFarlane's approval rating as Adamas Pharmaceuticals' CEO?

2 employees have rated Adamas Pharmaceuticals Chief Executive Officer Neil McFarlane on Glassdoor.com. Neil McFarlane has an approval rating of 100% among the company's employees. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV).

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $8.22.

How much money does Adamas Pharmaceuticals make?

Adamas Pharmaceuticals (NASDAQ:ADMS) has a market capitalization of $376.37 million and generates $74.46 million in revenue each year. The specialty pharmaceutical company earns $-57,400,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis.

How many employees does Adamas Pharmaceuticals have?

The company employs 138 workers across the globe.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The official website for the company is www.adamaspharma.com. The specialty pharmaceutical company can be reached via phone at (510) 450-3500, via email at ir@adamaspharma.com, or via fax at 510-428-0519.

This page (NASDAQ:ADMS) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -